UniProt Q8WTQ7 · PDB · AlphaFold · Substrate: Casein · Clone: full-lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Repotrectinib | 95.5% | 4.5% | 84.21 | 0.608 |
| 2 | Midostaurin | 92.3% | 7.7% | 78.64 | 0.500 |
| 3 | Lorlatinib | 92.0% | 8.0% | 97.24 | 0.694 |
| 4 | Upadacitinib | 57.2% | 42.8% | 97.98 | 0.663 |
| 5 | Capivasertib | 51.8% | 48.2% | 96.48 | 0.644 |
| 6 | Darovasertib | 47.1% | 52.9% | 96.99 | 0.719 |
| 7 | Defactinib | 25.6% | 74.4% | 92.68 | 0.450 |
| 8 | Sunitinib | 25.1% | 74.9% | 91.73 | 0.524 |
| 9 | Baricitinib | 20.8% | 79.2% | 97.99 | 0.616 |
| 10 | Ceritinib | 13.9% | 86.1% | 95.44 | 0.618 |
| 11 | Deucravacitinib | 12.8% | 87.2% | 98.99 | 0.718 |
| 12 | Entrectinib | 10.9% | 89.1% | 93.69 | 0.671 |
| 13 | Umbralisib | 10.4% | 89.6% | 98.74 | 0.670 |
| 14 | Alectinib | 9.8% | 90.2% | 95.49 | 0.651 |
| 15 | Pacritinib | 9.8% | 90.2% | 88.64 | 0.452 |
| 16 | Ruxolitinib | 9.6% | 90.4% | 98.25 | 0.592 |
| 17 | Futibatinib | 8.8% | 91.2% | 98.48 | 0.718 |
| 18 | Erdafitinib | 8.8% | 91.2% | 95.71 | 0.737 |
| 19 | Bosutinib | 8.4% | 91.6% | 87.22 | 0.555 |
| 20 | Canertinib | 8.3% | 91.7% | 96.49 | 0.671 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.02
- Epithelial log2(TPM+1): 0.05
- Fold change: -0.03
- Status: No significant change
High-confidence drugs
- Lorlatinib — inh 92.0% · KISS 42.20
- Repotrectinib — inh 95.5% · KISS 30.70
- Midostaurin — inh 92.3% · KISS 22.12
Selectivity landscape vs inhibition on GRK7
Each point is one of the 92 approved drugs; color = inhibition % on GRK7.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…